InvestSMART

Vitrafy Life Sciences Limited (ASX:VFY)

ALERT: Price-sensitive ASX Announcement for VFY
Current share price for VFY : $3.200 -0.6 (-15.79%)+
Announcement
Release
12 Jun 2026 9:32AM
Price at Release
$3.800
Full Release
download
Summary
Vitrafy Life Sciences Limited has successfully raised A$30 million through an institutional placement, priced at A$2.60 per share, which represents a discount to both the last closing price and the 15-day VWAP. The raised capital will fund the manufacturing of Guardion devices and support the expansion of Vitrafy's US operations. Additionally, the company announced a Share Purchase Plan (SPP) to collect up to A$2 million more, targeting eligible shareholders in Australia and New Zealand. The placement and SPP are structured to not require shareholder approval, aligning with ASX listing rules. Vitrafy is leveraging this capital to accelerate its growth in the US blood market and further its commercialisation efforts.
Key Points
  • Vitrafy Life Sciences Limited completed a A$30 million institutional placement.
  • The placement was priced at A$2.60 per share, representing a discount to the last closing price and VWAP.
  • The funds will be used to manufacture the Guardion devices and expand US operations.
  • A Share Purchase Plan (SPP) will also be offered to raise an additional A$2 million.
  • The SPP is open to shareholders with a registered address in Australia or New Zealand.
  • New shares from the SPP will be issued at the same price as the placement.
  • Key dates include the commencement of trading on June 12, 2026, and the SPP offer period in late June and early July.
  • The placement does not require shareholder approval as it falls within the company's ASX listing rule capacities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.